IGFBP7 knockdown or neutralization decreases the progression of ALL in vivo. (A) NOD/SCID mice were transplanted with 10 million sh.959 or Scramble (Scr) ALL cell lines. After 4 (REH, RS4;11, and 697) to 6 (TALL-1 and CCRF-CEM) weeks, animals were killed and evaluated for the percentage of leukemia (hCD45⁺) cells in the peripheral blood (PBL), spleen, liver, and bone marrow (BM) by flow cytometry. Bars represent means ± SE for 3 animals. Statistical analysis was done by 2-way ANOVA and Bonferroni posttests (**P ≤ .01 and ****P ≤ .0001). (B) Kaplan-Meier survival curves of NOD/SCID mice (5 animals per group) transplanted with sh.959 or Scramble (Scr) ALL cells. (C) Survival curves of NOD/SCID mice transplanted with a patient-derived BCP-ALL xenograft (B1421-PDX) and treated with the anti-IGFBP7 (clone C311) or anti-PSA antibody, as above, for 4 weeks. Treatment of mice (4 animals per group) started when half of the animals had ≥0.5% of leukemia cells